About: The natural compound silvestrol inhibits hepatitis E virus (HEV) replication in vitro and in vivo

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The natural compound silvestrol inhibits hepatitis E virus (HEV) replication in vitro and in vivo Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	The natural compound silvestrol inhibits hepatitis E virus (HEV) replication in vitro and in vivo
Creator	Kinast, Volker Steinmann, Eike Todt, Daniel Meuleman, Philip Friesland, Martina Verhoye, Lieven Engelmann, Michael Behrendt, Patrick Moeller, Nora Praditya, Dimas Loan, Viet Sayed, Ibrahim Thi, Dao
Source	Elsevier; Medline; PMC
abstract	Hepatitis E virus (HEV) is the causative agent of hepatitis E in humans and a member of the genus Orthohepevirus in the family Hepeviridae. HEV infections are the common cause of acute hepatitis but can also take chronic courses. Ribavirin is the treatment of choice for most patients and type I interferon (IFN) has been evaluated in a few infected transplantation patients in vivo. However, no effective and specific treatments against HEV infections are currently available. In this study, we evaluated the natural compound silvestrol, isolated from the plant Aglaia foveolata, and known for its specific inhibition of the DEAD-box RNA helicase eIF4A in state-of-the-art HEV experimental model systems. Silvestrol blocked HEV replication of different subgenomic replicons in a dose-dependent manner at low nanomolar concentrations and acted additive to ribavirin (RBV). In addition, HEV p6-based full length replication and production of infectious particles was reduced in the presence of silvestrol. A pangenotypic effect of the compound was further demonstrated with primary isolates from four different human genotypes in HEV infection experiments of hepatocyte-like cells derived from human embryonic and induced pluripotent stem cells. In vivo, HEV RNA levels rapidly declined in the feces of treated mice while no effect was observed in the vehicle treated control animals. In conclusion, silvestrol could be identified as pangenotypic HEV replication inhibitor in vitro with additive effect to RBV and further demonstrated high potency in vivo. The compound therefore may be considered in future treatment strategies of chronic hepatitis E in immunocompromised patients.
has issue date	2018-07-20(xsd:dateTime)
bibo:doi	10.1016/j.antiviral.2018.07.010
bibo:pmid	30036559
has license	no-cc
sha1sum (hex)	962fe9022b7ecbb15c50380673d47716888060d4
schema:url	https://doi.org/10.1016/j.antiviral.2018.07.010
resource representing a document's title	The natural compound silvestrol inhibits hepatitis E virus (HEV) replication in vitro and in vivo
has PubMed Central identifier	PMC7113770
has PubMed identifier	30036559
schema:publication	Antiviral Res
resource representing a document's body	covid:962fe9022b7ecbb15c50380673d47716888060d4#body_text
is schema:about of	named entity 'vivo' named entity 'IN VITRO' named entity 'HEV' named entity 'GENUS' named entity 'SPECIFIC' named entity 'HUMANS' named entity 'TYPE I INTERFERON' named entity 'CURRENTLY' named entity 'HEPATITIS E' named entity 'CAUSE' named entity 'TREATMENTS' named entity 'TREATMENT' named entity 'TRANSPLANTATION' named entity 'INFECTIONS' named entity 'IN VIVO' named entity 'CAUSATIVE AGENT' named entity 'REPLICATION' named entity 'INTERFERON ' named entity 'RIBAVIRIN' named entity 'HEPATITIS E VIRUS' named entity 'CHRONIC' named entity 'MEMBER OF' named entity 'EVALUATED' named entity 'HEPATITIS E VIRUS' named entity 'ACUTE HEPATITIS' named entity 'EFFECTIVE' named entity 'NATURAL COMPOUND' named entity 'AVAILABLE' named entity 'FAMILY HEPEVIRIDAE' named entity 'IN VIVO' named entity 'BUT' named entity 'ORTHOHEPEVIRUS' named entity 'COURSES' named entity 'PATIENTS' named entity 'SILVESTROL' named entity 'COMMON' named entity 'INFECTED' named entity 'CHOICE' covid:arg/962fe9022b7ecbb15c50380673d47716888060d4 named entity 'common' named entity 'chronic' named entity 'causative' named entity 'type I interferon' named entity 'swine' named entity 'HEV' named entity 'mRNA translation' named entity 'silvestrol' named entity 'viral RNA' named entity 'replicons' named entity 'HEV' named entity 'Intracellular' named entity 'luciferase' named entity 'translation initiation' named entity 'viral RNA' named entity 'genotypes' named entity 'antiviral' named entity 'nanomolar' named entity 'antiviral activity' named entity 'hepatocyte' named entity 'HLCs' named entity 'silvestrol' named entity 'intraperitoneal' named entity 'GE Healthcare' named entity 'eIF4F' named entity 'mutation' named entity 'dose-response curves' named entity 'HEV' named entity 'Hepatitis E virus' named entity 'gentamicin'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software